We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

25 hedge funds and large institutions have $166K invested in Matinas BioPharma in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

14% more funds holding

Funds holding: 22 → 25 (+3)

0.97% less ownership

Funds ownership: 7.26% → 6.29% (-0.97%)

14% less capital invested

Capital invested by funds: $194K → $166K (-$27.6K)

Holders
25
Holders Change
+3
Holders Change %
+13.64%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$12.4K
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.49K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.94K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.07K
5
CAM
Costello Asset Management
Pennsylvania
+$118

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$27.7K
2
SIG
Sargent Investment Group
Maryland
-$13.3K
3
UBS Group
UBS Group
Switzerland
-$6.32K
4
IA
IFP Advisors
Florida
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$31.1K -$27.7K -46,769 -44%
BlackRock
2
BlackRock
New York
$25.8K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$24.3K +$1.94K +3,274 +8%
SIG
4
Sargent Investment Group
Maryland
$21.7K -$13.3K -22,400 -35%
HIW
5
Holos Integrated Wealth
Pennsylvania
$16.9K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$13.3K +$1.07K +1,808 +8%
Renaissance Technologies
7
Renaissance Technologies
New York
$11.6K +$2.49K +4,200 +23%
TSS
8
Two Sigma Securities
New York
$10.9K +$12.4K +20,974 New
State Street
9
State Street
Massachusetts
$7.97K – – –
UBS Group
10
UBS Group
Switzerland
$853 -$6.32K -10,673 -87%
TRCT
11
Tower Research Capital (TRC)
New York
$576 +$4 +6 +0.5%
Bank of America
12
Bank of America
North Carolina
$507 +$1 +1 +0.1%
JP Morgan Chase
13
JP Morgan Chase
New York
$470 – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$108 +$6 +10 +5%
CAM
15
Costello Asset Management
Pennsylvania
$104 +$118 +200 New
Morgan Stanley
16
Morgan Stanley
New York
$75 – – –
Wells Fargo
17
Wells Fargo
California
$53 – – –
SPIA
18
Steward Partners Investment Advisory
New York
$32 – – –
EWA
19
EverSource Wealth Advisors
Alabama
$31 – – –
VFM
20
Vision Financial Markets
Connecticut
$21 +$24 +40 New
RIL
21
Rothschild Investment LLC
Illinois
$7 – – –
SS
22
SBI Securities
Japan
$7 +$1 +2 +18%
FFA
23
Farther Finance Advisors
California
$3 +$3 +5 New
NA
24
NewEdge Advisors
Louisiana
$1 – – –
Fidelity Investments
25
Fidelity Investments
Massachusetts
$1 +$1 +1 New
1
2

MTNB Hedge Fund Activity: Q1 2025 in Review

25 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2025, worth a combined $166K — down 14% from $194K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MTNB positions and 2 closed out — a net gain of 3 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $12.4K. The largest seller was Vanguard Group, cutting an estimated $27.7K.

  • 25 institutional investors held Matinas BioPharma (MTNB) as of Q1 2025, up from 22 in Q4 2024.
  • Funds reported $166K of Matinas BioPharma stock for Q1 2025, down 14% quarter-over-quarter.
  • 5 funds opened new Matinas BioPharma positions in Q1 2025 and 2 closed out, a net change of +3 holders.
  • The largest Matinas BioPharma buyer in Q1 2025 was Two Sigma Securities, an estimated $12.4K added.
  • The largest Matinas BioPharma seller in Q1 2025 was Vanguard Group, an estimated $27.7K sold.

Based on aggregated 13F filings for Q1 2025.